相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
M. Borner et al.
ANNALS OF ONCOLOGY (2008)
Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
Bret B. Friday et al.
CLINICAL CANCER RESEARCH (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
F. Cappuzzo et al.
ANNALS OF ONCOLOGY (2008)
First-line single-agent cetuximab in patients with advanced colorectal cancer
A. Pessino et al.
ANNALS OF ONCOLOGY (2008)
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
W. De Roock et al.
ANNALS OF ONCOLOGY (2008)
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2008)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the Anti-EGFR monoclonal antibody cetuximab
Yang Lu et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer
Alberto Malesci et al.
CLINICAL CANCER RESEARCH (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy
F. Di Fiore et al.
BRITISH JOURNAL OF CANCER (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma
AP Venook
CANCER (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Drug therapy - Systemic therapy for colorectal cancer
JA Meyerhardt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer
M Frattini et al.
ONCOGENE (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Different genetic features associated with colon and rectal carcinogenesis
M Frattini et al.
CLINICAL CANCER RESEARCH (2004)
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
GR Deng et al.
CLINICAL CANCER RESEARCH (2004)
Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases
R Haddad et al.
ANNALS OF SURGICAL ONCOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Tumorigenesis -: RAF/RAS oncogenes and mismatch-repair status
H Rajagopalan et al.
NATURE (2002)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
BH Zhang et al.
EMBO JOURNAL (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
